Donepezil Market

The Donepezil market is projected to grow at a steady CAGR of 5.7% during the forecast period 2025–2035. The growth is primarily driven by the rising global prevalence of Alzheimer’s disease and other neurodegenerative disorders, particularly among the aging population. Donepezil, a cholinesterase inhibitor, is widely prescribed for the symptomatic treatment of cognitive decline associated with Alzheimer’s and other forms of dementia. Additionally, off-label use for mild cognitive impairment is gaining attention, further contributing to its market demand. The increasing burden of neurological diseases, growing awareness of early intervention, and advances in diagnostic technologies are all key factors supporting the expansion of Donepezil usage.

Regionally, North America dominates the Donepezil market, which is supported by a high geriatric population, strong healthcare infrastructure, and extensive insurance coverage for neurodegenerative disease treatments. Certainly, the Asia-Pacific region is expected to witness the fastest growth, driven by growing healthcare access, increasing diagnosis rates, and government programs targeting cognitive health, particularly in countries like Japan, China, and India.

This report delves into a comprehensive analysis of the Donepezil market across various product types such as tablets, capsules, oral solutions/syrups, and transdermal patches. It also examines applications in Alzheimer’s treatment, other forms of dementia, and mild cognitive impairment, as well as key end-user segments including pharmaceutical manufacturers, hospitals and clinics, retail and online pharmacies, and research institutions. The rising need for effective cognitive health therapies and continued R&D in neurology, where Donepezil API is expected to remain a cornerstone in neurodegenerative disease treatment protocols throughout the forecast period.